Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists von Roell, Daniela, Rösler, Thomas W., Hessenkemper, Wiebke, Kraft, Florian, Hauschild, Monique, Bartsch, Sophie, Abraham, Tsion E., Houtsmuller, Adriaan B., Matusch, Rudolf, van Royen, Martin E., Baniahmad, Aria

Volltext

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma von Robert, Caroline, Grob, Jean J, Stroyakovskiy, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Evgeny, Chiarion Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Bondarenko, Igor, Gogas, Helen, Mandalá, Mario, Haanen, John B.A.G, Lebbé, Celeste, Mackiewicz, Andrzej, Rutkowski, Piotr, Nathan, Paul D, Ribas, Antoni, Davies, Michael A, Flaherty, Keith T, Burgess, Paul, Tan, Monique, Gasal, Eduard, Voi, Maurizio, Schadendorf, Dirk, Long, Georgina V

Volltext

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma von Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M, Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V, Schadendorf, Dirk

Volltext

Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma von Long, Georgina V, Hauschild, Axel, Santinami, Mario, Kirkwood, John M, Atkinson, Victoria, Mandala, Mario, Merelli, Barbara, Sileni, Vanna Chiarion, Nyakas, Marta, Haydon, Andrew, Dutriaux, Caroline, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Schadendorf, Dirk, Lesimple, Thierry, Plummer, Ruth, Larkin, James, Tan, Monique, Adnaik, Sachin Bajirao, Burgess, Paul, Jandoo, Tarveen, Dummer, Reinhard

Volltext

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma von Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M, Chiarion Sileni, Vanna, Larkin, James, Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Lesimple, Thierry, Plummer, Ruth, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V, Schadendorf, Dirk

Volltext

Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD von Hauschild, Axel, Dummer, Reinhard, Santinami, Mario, Atkinson, Victoria, Mandalà, Mario, Kirkwood, John M., Chiarion Sileni, Vanna, Larkin, James M. G., Nyakas, Marta, Dutriaux, Caroline, Haydon, Andrew Mark, Robert, Caroline, Mortier, Laurent, Schachter, Jacob, Dasgupta, Kohinoor, Gasal, Eduard, Tan, Monique, Long, Georgina V., Schadendorf, Dirk

Volltext

Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600 –mutant unresectable or metastatic melanoma von Nathan, Paul D., Robert, Caroline, Grob, Jean Jacques, Stroyakovskiy, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Eugeny, Chiarion Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Bondarenko, Igor, Davies, Michael A., Ribas, Antoni, Flaherty, Keith, Burgess, Paul, Tan, Monique, Gasal, Eduard, Schadendorf, Dirk, Long, Georgina V.

Volltext

Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study von Busiah, Kanetee, MD, Drunat, Séverine, PharmD, Vaivre-Douret, Laurence, Prof, Bonnefond, Amélie, PhD, Simon, Albane, MD, Flechtner, Isabelle, MD, Gérard, Bénédicte, PharmD, Pouvreau, Nathalie, MSc, Elie, Caroline, MD, Nimri, Revital, MD, Vries, Liat De, MD, Tubiana-Rufi, Nadia, MD, Metz, Chantal, MD, Bertrand, Anne-Marie, MD, Nivot-Adamiak, Sylvie, MD, de Kerdanet, Marc, MD, Stuckens, Chantal, MD, Jennane, Farida, MD, Souchon, Pierre-François, MD, Tallec, Claire Le, MD, Désirée, Christelle, MSc, Pereira, Sabrina, MSc, Dechaume, Aurélie, MSc, Robert, Jean-Jacques, Prof, Phillip, Moshe, Prof, Scharfmann, Raphaël, PhD, Czernichow, Paul, Prof, Froguel, Philippe, Prof, Vaxillaire, Martine, PharmD, Polak, Michel, Prof, Cavé, Hélène, Prof

Volltext

Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma von Kirkwood, John, Dummer, Reinhard, Hauschild, Axel, Santinami, Mario, Atkinson, Victoria, Sileni, Vanna, Larkin, James, Nyakas, Marta, Haydon, Andrew, Dutriaux, Caroline, Schachter, Jacob, Robert, Caroline, Mortier, Laurent, Banerjee, Hiya, Haas, Tomas, Tan, Monique, Lau, Mike, Schadendorf, Dirk, Long, Georgina, Mandala, Mario

Volltext

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis von Robert, Caroline, Grob, Jean, Stroyakovskiy, Daniil, Karaszewska, Boguslawa, Hauschild, Axel, Levchenko, Evgeny, Sileni, Vanna, Schachter, Jacob, Garbe, Claus, Bondarenko, Igor, Nathan, Paul, Ribas, Antoni, Davies, Michael, Flaherty, Keith, Burgess, Paul, Tan, Monique, Gasal, Eduard, Schadendorf, Dirk, Long, Georgina

Volltext